Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 98

1.

Mutations in the RAS-BRAF-MAPK-ERK pathway define a specific subgroup of patients with adverse clinical features and provide new therapeutic options in chronic lymphocytic leukemia.

Giménez N, Martínez-Trillos A, Montraveta A, Lopez-Guerra M, Rosich L, Nadeu F, Valero JG, Aymerich M, Magnano L, Rozman M, Matutes E, Delgado J, Baumann T, Gine E, González M, Alcoceba M, Terol MJ, Navarro B, Colado E, Payer AR, Puente XS, López-Otín C, Lopez-Guillermo A, Campo E, Colomer D, Villamor N.

Haematologica. 2019 Mar;104(3):576-586. doi: 10.3324/haematol.2018.196931. Epub 2018 Sep 27.

2.

BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia.

Yaktapour N, Meiss F, Mastroianni J, Zenz T, Andrlova H, Mathew NR, Claus R, Hutter B, Fröhling S, Brors B, Pfeifer D, Pantic M, Bartsch I, Spehl TS, Meyer PT, Duyster J, Zirlik K, Brummer T, Zeiser R.

J Clin Invest. 2014 Nov;124(11):5074-84. doi: 10.1172/JCI76539. Epub 2014 Oct 20.

3.

Relationships among KRAS mutation status, expression of RAS pathway signaling molecules, and clinicopathological features and prognosis of patients with colorectal cancer.

Wan XB, Wang AQ, Cao J, Dong ZC, Li N, Yang S, Sun MM, Li Z, Luo SX.

World J Gastroenterol. 2019 Feb 21;25(7):808-823. doi: 10.3748/wjg.v25.i7.808.

4.

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells.

Cesi G, Walbrecq G, Zimmer A, Kreis S, Haan C.

Mol Cancer. 2017 Jun 8;16(1):102. doi: 10.1186/s12943-017-0667-y.

5.

Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation.

Lionetti M, Barbieri M, Todoerti K, Agnelli L, Marzorati S, Fabris S, Ciceri G, Galletti S, Milesi G, Manzoni M, Mazzoni M, Greco A, Tonon G, Musto P, Baldini L, Neri A.

Oncotarget. 2015 Sep 15;6(27):24205-17.

6.

Molecular signaling in multiple myeloma: association of RAS/RAF mutations and MEK/ERK pathway activation.

Xu J, Pfarr N, Endris V, Mai EK, Md Hanafiah NH, Lehners N, Penzel R, Weichert W, Ho AD, Schirmacher P, Goldschmidt H, Andrulis M, Raab MS.

Oncogenesis. 2017 May 15;6(5):e337. doi: 10.1038/oncsis.2017.36.

7.

Mutations affecting BRAF, EGFR, PIK3CA, and KRAS are not associated with sporadic vestibular schwannomas.

de Vries M, Bruijn IB, Cleton-Jansen AM, Malessy MJ, van der Mey AG, Hogendoorn PC.

Virchows Arch. 2013 Feb;462(2):211-7. doi: 10.1007/s00428-012-1342-8. Epub 2012 Dec 8.

PMID:
23224067
8.

Mechanism of RAF isoform switching induced by oncogenic RAS in melanoma.

Dumaz N.

Small GTPases. 2011 Sep;2(5):289-292. Epub 2011 Sep 1.

9.

Mutations of BRAF and RAS are rare events in germ cell tumours.

Sommerer F, Hengge UR, Markwarth A, Vomschloss S, Stolzenburg JU, Wittekind C, Tannapfel A.

Int J Cancer. 2005 Jan 10;113(2):329-35.

10.

A new water soluble MAPK activator exerts antitumor activity in melanoma cells resistant to the BRAF inhibitor vemurafenib.

Graziani G, Artuso S, De Luca A, Muzi A, Rotili D, Scimeca M, Atzori MG, Ceci C, Mai A, Leonetti C, Levati L, Bonanno E, Tentori L, Caccuri AM.

Biochem Pharmacol. 2015 May 1;95(1):16-27. doi: 10.1016/j.bcp.2015.03.004. Epub 2015 Mar 17.

PMID:
25795251
11.

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile.

Wiestner A, Rosenwald A, Barry TS, Wright G, Davis RE, Henrickson SE, Zhao H, Ibbotson RE, Orchard JA, Davis Z, Stetler-Stevenson M, Raffeld M, Arthur DC, Marti GE, Wilson WH, Hamblin TJ, Oscier DG, Staudt LM.

Blood. 2003 Jun 15;101(12):4944-51. Epub 2003 Feb 20.

12.

Loss of NF1 in cutaneous melanoma is associated with RAS activation and MEK dependence.

Nissan MH, Pratilas CA, Jones AM, Ramirez R, Won H, Liu C, Tiwari S, Kong L, Hanrahan AJ, Yao Z, Merghoub T, Ribas A, Chapman PB, Yaeger R, Taylor BS, Schultz N, Berger MF, Rosen N, Solit DB.

Cancer Res. 2014 Apr 15;74(8):2340-50. doi: 10.1158/0008-5472.CAN-13-2625. Epub 2014 Feb 27.

13.

BRAF kinase domain mutations are present in a subset of chronic myelomonocytic leukemia with wild-type RAS.

Zhang L, Singh RR, Patel KP, Stingo F, Routbort M, You MJ, Miranda RN, Garcia-Manero G, Kantarjian HM, Medeiros LJ, Luthra R, Khoury JD.

Am J Hematol. 2014 May;89(5):499-504. doi: 10.1002/ajh.23652. Epub 2014 Feb 10.

14.

Antitumor activity of the selective pan-RAF inhibitor TAK-632 in BRAF inhibitor-resistant melanoma.

Nakamura A, Arita T, Tsuchiya S, Donelan J, Chouitar J, Carideo E, Galvin K, Okaniwa M, Ishikawa T, Yoshida S.

Cancer Res. 2013 Dec 1;73(23):7043-55. doi: 10.1158/0008-5472.CAN-13-1825. Epub 2013 Oct 11.

15.

Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.

Ouyang B, Knauf JA, Smith EP, Zhang L, Ramsey T, Yusuff N, Batt D, Fagin JA.

Clin Cancer Res. 2006 Mar 15;12(6):1785-93.

16.

Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.

Juanpere N, Agell L, Lorenzo M, de Muga S, López-Vilaró L, Murillo R, Mojal S, Serrano S, Lorente JA, Lloreta J, Hernández S.

Hum Pathol. 2012 Oct;43(10):1573-82. doi: 10.1016/j.humpath.2011.10.026. Epub 2012 Mar 12.

PMID:
22417847
17.

High resolution melting analysis of KRAS, BRAF and PIK3CA in KRAS exon 2 wild-type metastatic colorectal cancer.

Guedes JG, Veiga I, Rocha P, Pinto P, Pinto C, Pinheiro M, Peixoto A, Fragoso M, Raimundo A, Ferreira P, Machado M, Sousa N, Lopes P, Araújo A, Macedo J, Alves F, Coutinho C, Henrique R, Santos LL, Teixeira MR.

BMC Cancer. 2013 Apr 1;13:169. doi: 10.1186/1471-2407-13-169.

18.

Novel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumors.

Agaram NP, Wong GC, Guo T, Maki RG, Singer S, Dematteo RP, Besmer P, Antonescu CR.

Genes Chromosomes Cancer. 2008 Oct;47(10):853-9. doi: 10.1002/gcc.20589.

19.

Constitutive activation of the Ras-Raf signaling pathway in metastatic melanoma is associated with poor prognosis.

Houben R, Becker JC, Kappel A, Terheyden P, Bröcker EB, Goetz R, Rapp UR.

J Carcinog. 2004 Mar 26;3:6. doi: 10.1186/1477-3163-3-6. eCollection 2004.

20.

Mitogen-activated protein kinase (MAPK) hyperactivation and enhanced NRAS expression drive acquired vemurafenib resistance in V600E BRAF melanoma cells.

Lidsky M, Antoun G, Speicher P, Adams B, Turley R, Augustine C, Tyler D, Ali-Osman F.

J Biol Chem. 2014 Oct 3;289(40):27714-26. doi: 10.1074/jbc.M113.532432. Epub 2014 Jul 25.

Supplemental Content

Support Center